Pembroke Management’s Ligand Pharmaceuticals LGND Stock Holding History

Pembroke Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.7M	Buy	+40,277	New	+$9.49M	2%	20

Other funds holding LGND

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS)

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

Pembroke Management's LGND Position: Q2 2026 in Review

Pembroke Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 40,277 shares worth $12.7M. The stake represents 2% of the portfolio and ranks #20 among its holdings.

64 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Pembroke Management held 40,277 shares of Ligand Pharmaceuticals worth $12.7M as of Q2 2026.
Ligand Pharmaceuticals was a new Pembroke Management position in Q2 2026.
Ligand Pharmaceuticals made up 2% of Pembroke Management's portfolio in Q2 2026, its #20 holding.
64 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Pembroke Management's 13F filing for Q2 2026, filed 22 Jul 2026.